Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
54868-5667-03 54868-5667 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Sept. 8, 2006 No Longer Used
00093-8229-28 00093-8229 Sunitinib Malate Sunitinib Malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8231-28 00093-8231 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8224-28 00093-8224 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-8199-28 00093-8199 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec. 22, 2021 In Use
00093-7662-56 00093-7662 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Dec. 8, 2021 In Use
51862-0682-00 51862-0682 TAMOXIFEN CITRATE SOLTAMOX 20.0 mg/10mL Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 6, 2021 In Use
51862-0682-01 51862-0682 TAMOXIFEN CITRATE SOLTAMOX 20.0 mg/10mL Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 18, 2021 In Use
63739-0143-10 63739-0143 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 14, 2021 In Use
68788-8112-03 68788-8112 Medroxyprogesterone Acetate Medroxyprogesterone Acetate 5.0 mg/1 Hormonal Therapy Progestin Oral Dec. 6, 2021 In Use
70771-1626-08 70771-1626 Fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
70710-1688-08 70710-1688 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
75834-0132-05 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0132-14 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-05 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-14 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-05 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-14 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-05 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-14 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-05 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-14 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
80425-0072-01 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-02 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-03 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-04 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-05 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
42291-0321-01 42291-0321 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral July 23, 2013 In Use
42291-0505-01 42291-0505 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 5, 2020 In Use
42388-0013-14 42388-0013 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
43975-0256-05 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
43975-0256-14 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
44087-3535-01 44087-3535 Avelumab Bavencio 20.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 23, 2017 In Use
50742-0404-01 50742-0404 Topotecan Topotecan 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 7, 2016 In Use
50742-0423-10 50742-0423 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0420-01 50742-0420 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0427-05 50742-0427 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sept. 27, 2018 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan. 27, 2021 In Use
54879-0021-01 54879-0021 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
54879-0022-01 54879-0022 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
72187-0401-01 72187-0401 Tagraxofusp Elzonris 1000.0 ug/mL Immunotherapy Fusion Protein IL3/ CD123 Intravenous Jan. 18, 2019 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
50242-0245-01 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
50242-0260-01 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0260-86 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sept. 20, 2021 In Use
57277-0107-45 57277-0107 carboplatin Injection Carboplatin 450.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
59148-0070-91 59148-0070 Busulfan Busulfex 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb. 4, 1999 In Use
61126-0004-01 61126-0004 Cisplatin Platinol-AQ 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 In Use
61703-0303-46 61703-0303 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 31, 1990 In Use
62756-0826-40 62756-0826 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 20, 2012 In Use
62756-0827-40 62756-0827 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 20, 2012 In Use
63304-0158-01 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0158-30 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0962-01 63304-0962 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0962-30 63304-0962 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63323-0637-10 63323-0637 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Aug. 31, 2018 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 1, 2019 In Use
63759-0003-01 63759-0003 azacitidine for Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 5, 2016 In Use
63759-3000-01 63759-3000 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 31, 2016 In Use
63759-3001-01 63759-3001 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 31, 2016 In Use
64842-1020-01 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 7, 2015 In Use
64842-1020-02 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 11, 2015 In Use
64842-1020-03 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 21, 2015 In Use
64842-1025-01 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 7, 2015 In Use
64842-1025-02 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 11, 2015 In Use
64842-1025-03 64842-1025 Trifluridine and Tipiracil Lonsurf 6.14 mg/1, 15.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct. 21, 2015 In Use
66336-0338-21 66336-0338 METHOTREXATE Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
66336-0338-30 66336-0338 METHOTREXATE Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
66758-0051-01 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66758-0051-03 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66758-0051-05 66758-0051 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 25, 2011 In Use
66828-0030-01 66828-0030 Imatinib Mesylate Gleevec 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 15, 2001 In Use
53217-0374-10 53217-0374 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 17, 2018 In Use
67877-0537-07 67877-0537 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0537-14 67877-0537 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0538-07 67877-0538 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0538-14 67877-0538 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0539-07 67877-0539 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0539-14 67877-0539 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0540-07 67877-0540 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0540-14 67877-0540 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0541-07 67877-0541 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0541-14 67877-0541 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
67877-0542-07 67877-0542 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
68151-1305-00 68151-1305 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 No Longer Used
68382-0775-01 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-05 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-10 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-16 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-60 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
68382-0775-77 68382-0775 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
69097-0313-37 69097-0313 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0314-42 69097-0314 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use

Found 10,000 results in 10 milliseconds — Export these results